Daniel Knowland

Daniel Knowland

Auto-generated profile, based on publicly available information

Daniel Knowland

Neurosciences Graduate Program, University of California San Diego, La Jolla, California

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Neuron
Verified
Journal Article
Closed access
DKDaniel Knowland
Daniel Knowland
AAAhmet Arac
Ahmet Arac
KSKohei J. Sekiguchi
Kohei J. Sekiguchi
MHMartin Hsu
Martin Hsu
SLSarah Elizabeth Lutz
Sarah Elizabeth Lutz
DADritan Agalliu
Dritan Agalliu

14 December 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TDThamotharampillai Dileepan
Thamotharampillai Dileepan
ESErica D. Smith
Erica D. Smith
DKDaniel Knowland
Daniel Knowland
MHMartin Hsu
Martin Hsu
MPMaryann Platt
Maryann Platt
PCP. Patrick Cleary
P. Patrick Cleary
Group A streptococcal (GAS) infection induces the production of Abs that cross-react with host neuronal proteins, and these anti-GAS mimetic Abs are associated with autoimmune diseases of the CNS. However, the mechanisms that allow these Abs to cross the blood-brain barrier (BBB) and induce neuropathology remain unresolved. We have previously shown that GAS infection in mouse models induces a robust Th17 response in nasal-associated lymphoid tissue (NALT). Here, we identified GAS-specific Th17 cells in tonsils of humans naturally exposed to GAS, prompting us to explore whether GAS-specific CD4+ T cells home to mouse brains following i.n. infection. Intranasal challenge of repeatedly GAS-inoculated mice promoted migration of GAS-specific Th17 cells from NALT into the brain, BBB breakdown, serum IgG deposition, microglial activation, and loss of excitatory synaptic proteins under conditions in which no viable bacteria were detected in CNS tissue. CD4+ T cells were predominantly located in the olfactory bulb (OB) and in other brain regions that receive direct input from the OB. Together, these findings provide insight into the immunopathology of neuropsychiatric complications that are associated with GAS infections and suggest that crosstalk between the CNS and cellular immunity may be a general mechanism by which infectious agents exacerbate symptoms associated with other CNS autoimmune disorders.

1 December 2018 in Biological Psychiatry
Verified
Journal Article
Closed access
CBCindy Barrientos
Cindy Barrientos
DKDaniel Knowland
Daniel Knowland
MWMingche M.J. Wu
Mingche M.J. Wu
VLVaroth Lilascharoen
Varoth Lilascharoen
KHKee Wui Huang
Kee Wui Huang
BLByung Kook Lim
Byung Kook Lim

19 October 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DKDaniel Knowland
Daniel Knowland
SGShenyan Gu
Shenyan Gu
WEWilliam A. Eckert
William A. Eckert
GDG. Brent Dawe
G. Brent Dawe
JMJose A. Matta
Jose A. Matta
DBDavid S. Bredt
David S. Bredt
The α6β4 nicotinic acetylcholine receptor (nAChR) is enriched in dorsal root ganglia neurons and is an attractive non-opioid therapeutic target for pain. However, difficulty expressing human α6β4 receptors in recombinant systems has precluded drug discovery. Here, genome-wide screening identified accessory proteins that enable reconstitution of human α6β4 nAChRs. BARP, an auxiliary subunit of voltage-dependent calcium channels, promoted α6β4 surface expression while IRE1α, an unfolded protein response sensor, enhanced α6β4 receptor assembly. Effects on α6β4 involve BARP’s N-terminal region and IRE1α’s splicing of XBP1 mRNA. Furthermore, clinical efficacy of nicotinic agents in relieving neuropathic pain best correlated with their activity on α6β4. Finally, BARP-knockout, but not NACHO-knockout mice lacked nicotine-induced antiallodynia, highlighting the functional importance of α6β4 in pain. These results identify roles for IRE1α and BARP in neurotransmitter receptor assembly and unlock drug discovery for the previously elusive α6β4 receptor.